White Solid Apremilast CAS 608141-41-9 for Inflammation and Skin Conditions

Product Description:

Product Name: Apremilast CAS NO: 608141-41-9                                       

Synonyms:

QCR-202;

(S)-N-(2-(1-(3-ethoxy-4-m-ethoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide;

N-[2-[(1S)-1-(3-ethoxy-4-m-ethoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-y-l]acetamide;

Chemical & Physical Properties:

Appearance: White solid

Assay :≥99.0%

Density: 1.381

Boiling Point: 741.3±60.0℃(Predicted)

PKa: 14.01±0.20 (Predicted)

Flash Point: 402.1±32.9℃

Vapor Pressure: 0.0±2.5 mmHg at 25℃

Index of Refraction: 1.612

Apremilast , an oral phosphodiesterase 4 inhibitor is used in the treatment of psoriatic arthritis.

Apremilast (Otezla) was approved by the FDA on March 21, 2014 for the treatment of adult patients with active psoriatic arthritis. Apremilast is a member of a new class of oral small molecule inhibitors of the phosphosphodiesterase 4 (PDE4) enzyme. When PDE4 is inhibited in immune cells, it results in elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, which can regulate inflammatory mediators. The current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults. Treating active psoriatic arthritis. It is also used to treat moderate to severe plaque psoriasis in certain patients.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.